One Probiotic Strain Tackled High-Fat-Diet Cholesterol From Three Directions at Once

High-fat diets drive dyslipidemia, a metabolic disorder marked by elevated total cholesterol and triglycerides, through multiple overlapping mechanisms, which is part of why it remains so difficult to treat with a single intervention. A new mouse study published in Food & Function by Zhou Z et al. suggests that a specific strain, Lactobacillus plantarum DY6, may work precisely because it does not rely on just one mechanism: it appears to hit cholesterol metabolism at the synthesis stage, the absorption stage, and the gut microbiota level, all at once. This is early, investigational research in mice, and whether these effects translate to humans remains an open question.

How L. plantarum DY6 Reduced Cholesterol Synthesis in the Liver

The most mechanistically detailed finding in the study concerns what happens in the liver. Mice fed a high-fat diet and given L. plantarum DY6 showed downregulated expression of two key genes: SREBP2 (sterol regulatory element-binding protein 2) and HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase). HMGCR is the enzyme that the cholesterol-lowering statin drug class targets directly, so its suppression here is notable. SREBP2 acts upstream as a transcription factor that switches on cholesterol synthesis genes, including HMGCR, when cellular cholesterol levels fall. By dampening both, L. plantarum DY6 appeared to reduce the liver's endogenous cholesterol production rather than simply shuttling cholesterol elsewhere. This finding aligns with broader evidence that gut microbiota influence cholesterol through bile acid metabolism and SCFA production, pathways the gut-liver axis connects directly.

Intestinal Cholesterol Absorption Blocked by NPC1L1 Suppression

Beyond synthesis, the study found that intestinal cholesterol absorption was curtailed through a separate molecular route. NPC1L1, the Niemann-Pick C1-Like 1 transporter responsible for shuttling dietary cholesterol from the gut lumen into intestinal cells, was suppressed in the DY6-treated mice. This is the same transporter that the cholesterol-absorption drug ezetimibe inhibits pharmacologically, making the parallel striking. Simultaneously, the hepatic liver X receptor alpha (LXRα) signaling pathway was activated. LXRα then upregulated two ATP-binding cassette transporters in the intestine, ABCG5 and ABCG8, which actively pump cholesterol back out of intestinal cells and into the gut lumen for excretion. The net effect was a two-pronged reduction: less cholesterol getting in through NPC1L1, and more cholesterol being pushed back out through ABCG5/ABCG8. A meta-analysis of randomized controlled trials has previously shown that certain Lactobacillus strains reduce total cholesterol and LDL-C in humans, though the mechanisms were not always well characterized.

Gut Microbiota Composition and Short-Chain Fatty Acid Production

The third major axis of effect involved the gut microbiota itself. L. plantarum DY6 administration changed the composition of the microbial community in the high-fat-diet mice, increasing populations of beneficial bacteria and boosting production of short-chain fatty acids (SCFAs). SCFAs, produced when gut bacteria ferment dietary fiber, have established roles in regulating lipid and glucose metabolism, suppressing hepatic cholesterol synthesis, and reinforcing gut barrier integrity. The study also assessed hepatic metabolite profiles and found these were altered in ways consistent with the observed lipid improvements. Taken together, the authors frame the mechanism as a gut-liver axis effect: changes in the gut microbiota send metabolic signals upstream to the liver that modulate cholesterol homeostasis. A randomized controlled trial of L. plantarum in mild hypercholesterolemia similarly found LDL-C reductions after 12 weeks, with efficacy partly dependent on baseline gut microbiota composition, suggesting the microbiome context matters in ways this mouse study cannot fully capture.

Limitations of a Mouse Model at This Stage

Several caveats apply. This is an animal study, and metabolic responses to high-fat diets and probiotic interventions differ substantially between mice and humans. The study does not report the specific dose of L. plantarum DY6 used, the duration of intervention, or the magnitude of lipid changes in quantitative terms beyond directional findings. It is also not clear how the DY6 strain compares to other L. plantarum strains already studied. Research on probiotics in type 2 diabetes-related dyslipidemia has found inconsistent effects on LDL-C and HDL-C, underscoring that strain selection, duration, and patient population all influence outcomes in ways that are not yet fully understood. The multi-target findings here are mechanistically plausible and scientifically interesting, but they remain preliminary until human trials replicate them.

What Comes Next for Probiotic-Based Cholesterol Research

The broader context matters here. Obesity-related dyslipidemia significantly elevates the risk of atherosclerotic cardiovascular disease, and existing pharmacological options, while effective, come with adherence challenges and side effects for some patients. A probiotic that works through complementary mechanisms to statins and ezetimibe could theoretically serve as an adjunct or, in mild cases, an alternative. The authors describe L. plantarum DY6 as a promising therapeutic strategy for preventing and mitigating high-fat-diet-induced dyslipidemia, which is an accurate framing given the data. A large meta-analysis of L. plantarum supplementation found that single-strain formulations and interventions longer than eight weeks produced the most consistent lipid improvements, which gives researchers a useful design template for the human trials needed to test DY6 specifically. For now, the mechanistic story from this study is compelling enough to justify that next step.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• This study was conducted entirely in mice; whether these effects translate to humans is unknown.
• No funding source was disclosed, so potential conflicts of interest cannot be assessed.
• Results have not yet been replicated in an independent study or tested in a human clinical trial.

Mouse-only preclinical study with no disclosed sample size for human subjects. Demonstrates a detailed mechanistic causal chain across cholesterol synthesis, absorption, and efflux pathways, but all findings are associative within an animal model and cannot be extrapolated to human outcomes without clinical replication. Not yet independently replicated.

References

1. Ziyue Zhou, Yin Mao, Jinyang Li, et al. (2026). Lactobacillus plantarum ameliorates high-fat-diet-induced dyslipidemia via cholesterol metabolism and gut microbiota modulation. Food & Function. https://doi.org/10.1039/d6fo00519e
2. Margaret Vourakis, Gaétan Mayer, Guy Rousseau (2021). The Role of Gut Microbiota on Cholesterol Metabolism in Atherosclerosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22158074
3. Xiaofei Yang, Changyou Wang, Xin Li, et al. (2015). Development and Molecular Cytogenetic Identification of a Novel Wheat–Leymus mollis Lm#7Ns (7D) Disomic Substitution Line with Stripe Rust Resistance. PLOS ONE. https://doi.org/10.1371/journal.pone.0140227
4. Felix Kerlikowsky, Mattea Müller, Theresa Greupner, Lena Amend, Till Strowig, Andreas Hahn (2023). Distinct Microbial Taxa Are Associated with LDL-Cholesterol Reduction after 12 Weeks of Lactobacillus plantarum Intake in Mild Hypercholesterolemia: Results of a Randomized Controlled Study. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-023-10191-2
5. Chen Wang, Chengcheng Zhang, Sijia Li, et al. (2020). Effects of Probiotic Supplementation on Dyslipidemia in Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Foods. https://doi.org/10.3390/foods9111540
6. Harold Edward Bays, Carol Kirkpatrick, Kevin C. Maki, et al. (2024). Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. Obesity Pillars. https://doi.org/10.1016/j.obpill.2024.100108
7. Jinshi Zuo, Dan Huang, Jie Liu, et al. (2025). Effect of Probiotics Containing Lactobacillus plantarum on Blood Lipids: Systematic Review, Meta-Analysis, and Network Pharmacological Analysis. Foods. https://doi.org/10.3390/foods14193300